Nintedanib Esylate Patent Expiration
Nintedanib Esylate is Used for slowing the decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc
Nintedanib Esylate Patents
Given below is the list of patents protecting Nintedanib Esylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ofev |
US9907756 (Pediatric) | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative | Dec 07, 2029 | Boehringer Ingelheim |
| Ofev |
US10105323 (Pediatric) | Pharmaceutical dosage form for immediate release of an indolinone derivative | Dec 04, 2029 | Boehringer Ingelheim |
| Ofev | US9907756 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative | Jun 07, 2029 | Boehringer Ingelheim |
| Ofev | US10105323 | Pharmaceutical dosage form for immediate release of an indolinone derivative | Jun 04, 2029 | Boehringer Ingelheim |
| Ofev |
US10154990 (Pediatric) | Medicaments for the treatment or prevention of fibrotic diseases | Jul 08, 2026 | Boehringer Ingelheim |
| Ofev |
US6762180 (Pediatric) | Substituted indolines which inhibit receptor tyrosine kinases | Apr 01, 2026 | Boehringer Ingelheim |
| Ofev | US10154990 | Medicaments for the treatment or prevention of fibrotic diseases | Jan 08, 2026 | Boehringer Ingelheim |
| Ofev | US6762180 | Substituted indolines which inhibit receptor tyrosine kinases | Oct 01, 2025 | Boehringer Ingelheim |
| Ofev | US7989474 | Use of Lck inhibitors for treatment of immunologic diseases |
Apr 06, 2024
(Expired) | Boehringer Ingelheim |
| Ofev | US7119093 | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
Feb 21, 2024
(Expired) | Boehringer Ingelheim |
Nintedanib Esylate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List